NASDAQ:KRRO Korro Bio (KRRO) Stock Price, News & Analysis $11.61 +0.41 (+3.66%) Closing price 04:00 PM EasternExtended Trading$12.39 +0.78 (+6.72%) As of 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Korro Bio Stock (NASDAQ:KRRO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Korro Bio alerts:Sign Up Key Stats Today's Range$11.25▼$12.1750-Day Range$9.15▼$14.3952-Week Range$5.20▼$55.89Volume231,201 shsAverage Volume201,998 shsMarket Capitalization$167.42 millionP/E RatioN/ADividend YieldN/APrice Target$16.71Consensus RatingModerate Buy Company Overview Korro Bio, Inc. is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases. The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics. Lead candidate KB103 is an investigational enzyme replacement therapy designed to address congenital hyperbilirubinemia by restoring deficient UGT1A1 activity. In parallel, Korro Bio is advancing a portfolio of live microbial drug candidates aimed at modulating the human microbiome to treat unmet medical needs in gastroenterology and oncology. These programs reflect the company’s dual focus on systemic enzyme therapies and targeted microbial approaches. Founded in 2019 and headquartered in Boston, Massachusetts, Korro Bio completed its initial public offering on the Nasdaq under the ticker KRRO in late 2021. The company collaborates with leading academic and industry partners to expand its enzyme discovery platform and accelerate translational research. Led by an experienced management team with backgrounds in biotherapeutics, protein science and drug development, Korro Bio serves a global pharmaceutical customer base and is committed to advancing innovative treatments from bench to bedside.AI Generated. May Contain Errors. Read More Korro Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreKRRO MarketRank™: Korro Bio scored higher than 65% of companies evaluated by MarketBeat, and ranked 288th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingKorro Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 2 strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialKorro Bio has a consensus price target of $16.71, representing about 44.0% upside from its current price of $11.61.Amount of Analyst CoverageKorro Bio has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Korro Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Korro Bio are expected to decrease in the coming year, from ($5.38) to ($6.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Korro Bio is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Korro Bio is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKorro Bio has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.12% of the float of Korro Bio has been sold short.Short Interest Ratio / Days to CoverKorro Bio has a short interest ratio ("days to cover") of 15.72, which indicates bearish sentiment.Change versus previous monthShort interest in Korro Bio has recently increased by 2.98%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKorro Bio does not currently pay a dividend.Dividend GrowthKorro Bio does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.73 News SentimentKorro Bio has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Korro Bio this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for KRRO on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days. Company Ownership3.9 / 5Insider TradingAcquiring Shares Cluster Insider Buying9 insiders have purchased shares of Korro Bio in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $18,412,560.00 in company stock, which represents 10.9981% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Korro Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $18,412,560.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders4.80% of the stock of Korro Bio is held by insiders.Percentage Held by Institutions13.18% of the stock of Korro Bio is held by institutions.Read more about Korro Bio's insider trading history. Receive KRRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Korro Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KRRO Stock News HeadlinesAnalysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Korro Bio (KRRO)May 20 at 3:40 PM | theglobeandmail.comCitigroup initiates coverage of Korro Bio (KRRO) with buy recommendationMay 20 at 3:40 PM | msn.com$7.7 billion in 90 days — and it all depends on ONE companySpaceX's S-1 filing reveals $7.7 billion spent on AI infrastructure in a single quarter - not chips, not software, but power infrastructure. The filing shows $23.85 billion in servers and $14 billion in construction in progress, all dependent on one company's hardware. Without this supplier, Colossus doesn't run and the $1.25 billion Anthropic pays monthly stops flowing. The stock is still trading like no one has read the filing - but analyst Dylan Jovine has, and he's releasing the name at no cost.May 22 at 1:00 AM | Behind the Markets (Ad)Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)May 19 at 7:00 AM | globenewswire.comKorro Bio, Inc. (NASDAQ:KRRO) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 19 at 2:22 AM | americanbankingnews.comKorro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 15, 2026 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: CareCloud (CCLD) and Korro Bio (KRRO)May 10, 2026 | theglobeandmail.comKorro Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 7, 2026 | globenewswire.comSee More Headlines KRRO Stock Analysis - Frequently Asked Questions How have KRRO shares performed this year? Korro Bio's stock was trading at $8.01 at the beginning of the year. Since then, KRRO stock has increased by 44.9% and is now trading at $11.61. How were Korro Bio's earnings last quarter? Korro Bio, Inc. (NASDAQ:KRRO) posted its earnings results on Thursday, May, 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by $0.09. Korro Bio had a negative net margin of 1,834.48% and a negative trailing twelve-month return on equity of 117.86%. When did Korro Bio IPO? Korro Bio (KRRO) raised $90 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. Who are Korro Bio's major shareholders? Korro Bio's top institutional investors include Affinity Asset Advisors LLC (4.90%), ADAR1 Capital Management LLC (3.75%), Renaissance Technologies LLC (0.94%) and Kalehua Capital Management LLC (0.76%). Insiders that own company stock include Lynx1 Capital Management Lp, Rick Yang, Paul Edward Walker, Mohamad Makhzoumi, Enterprise Associates 17 New, Anthony A Jr Florence, Venture Opportunity Fund Atlas, David L Lucchino and Vineet Agarwal. View institutional ownership trends. How do I buy shares of Korro Bio? Shares of KRRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Korro Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Korro Bio investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings5/07/2026Today5/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 KRRO's financial health is in the Green zone, according to TradeSmith. KRRO has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KRRO Previous SymbolNASDAQ:KRRO CIK1703647 Webwww.frequencytx.com Phone781-315-4600FaxN/AEmployees70Year Founded2018Price Target and Rating Average Price Target for Korro Bio$16.71 High Price Target$23.00 Low Price Target$10.00 Potential Upside/Downside+44.0%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($11.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$117.26 million Net Margins-1,834.48% Pretax Margin-2,935.09% Return on Equity-117.86% Return on Assets-71.04% Debt Debt-to-Equity RatioN/A Current Ratio8.13 Quick Ratio8.13 Sales & Book Value Annual Sales$6.39 million Price / Sales26.20 Cash FlowN/A Price / Cash FlowN/A Book Value$8.29 per share Price / Book1.40Miscellaneous Outstanding Shares14,420,000Free Float13,731,000Market Cap$167.42 million OptionableNo Data Beta3.07 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:KRRO) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Korro Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Korro Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
